Letermovir denied as non-formulary by Humana?

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Letermovir as Non-Formulary — and How to Appeal

A non-formulary denial for letermovir means Humana's current drug formulary either does not list letermovir at any tier or places it on a specialty tier requiring a formulary exception before it will be covered. For transplant patients in the active prophylaxis window, a non-formulary denial creates an urgent access problem. Formulary exception appeals are a well-established process under federal law, and letermovir's FDA-approved status and guideline support give these appeals strong footing.

## The Federal Legal Framework

• ERISA §503: employer-sponsored plans must provide a full-and-fair review and a written explanation of the formulary exception criteria.
• ACA §2719: independent external review is available if the formulary exception internal appeal is denied, within approximately four months of denial. Use the expedited track when post-transplant prophylaxis timing is urgent — Humana must respond within 72 hours on an expedited basis.
• ACA essential health benefit rules: for fully-insured individual and small-group plans, formulary exceptions must be available when no formulary alternative is medically appropriate.

## Concrete Appeal Steps and Timeline

1. Request a formulary exception: file a formal formulary exception request with Humana at the same time as or before filing a standard appeal — this is the fastest path to coverage. 2. Internal appeal: file within the timeframe in the denial letter. Request expedited processing given the transplant context. 3. Peer-to-peer call: the transplant prescriber should request an immediate peer-to-peer with Humana's pharmacist or medical director. 4. External review: if the exception and appeal are denied, file for IRO review. Non-formulary denials where no medically appropriate alternative exists are a core IRO reversal scenario.

## Documentation to Gather

• Formulary alternative contraindication or failure: if Humana's formulary includes an alternative antiviral for CMV prophylaxis, the prescriber must document why that alternative is clinically inappropriate for this specific patient — the mechanism difference, prior failure or intolerance, drug interactions with the immunosuppression regimen, or why letermovir is the guideline-recommended agent for this risk profile.
• Transplant clinical record: transplant type, date, CMV serostatus (donor and recipient), immunosuppression protocol — the full clinical picture supporting letermovir as the appropriate agent.
• Prescriber letter: explicit statement that no formulary alternative is clinically appropriate for this patient, referencing the relevant transplant guideline organization and the FDA-approved indication.
• Humana's formulary exception criteria: obtain the criteria before writing the appeal and address each one directly.
• Urgency documentation: chart note or letter documenting the prophylaxis window and the clinical risk of delay.

## Criteria-Mapping Structure

In the formulary exception request and appeal letter, build a two-column table: left column lists each of Humana's formulary exception criteria; right column provides the specific clinical fact that satisfies it. The central argument is medical necessity plus alternative inadequacy: letermovir is FDA-approved, guideline-supported, and no covered formulary alternative is appropriate for this patient. Address both elements with specific chart documentation, and the exception is highly likely to be granted — particularly when the prescriber joins with a peer-to-peer call.